跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 7,329 条关于
“CTX-187”
全部
7,329
临床试验
5,334
药物
1,321
机构
34
资讯
640
6个月前
Centauri Therapeutics Secures £6M from AMR Action Fund to Advance Novel Antibiotic CTX-187 Through Phase I Trials
去年
Compass Therapeutics' CTX-471 Shows Promise with NCAM Biomarker Correlation in Advanced Malignancies
2年前
FDA Clears Path for Cingulate's CTx-1301 ADHD Treatment NDA Submission
去年
Compass Therapeutics Receives FDA Fast Track Designation for CTX-009 Bispecific Antibody
3年前
Cingulate's Phase 3 Trial Shows Promising Results for Once-Daily ADHD Treatment CTx-1301
去年
Varda Space Industries Secures $187 Million Series C to Advance Microgravity Drug Manufacturing
去年
FDA Approves First Treatment for Cerebrotendinous Xanthomatosis (CTX), Offering Hope to Patients with Rare Genetic Disorder
去年
Cingulate's Once-Daily ADHD Drug CTx-1301 Shows Promising Safety Profile in Phase 3 Trials
去年
Cingulate Advances CTx-1301 for ADHD Treatment with Positive Phase III Safety Data and Upcoming FDA Pre-NDA Meeting
去年
Compass Therapeutics Reports Promising Clinical Data Across Bispecific Antibody Pipeline
第 1 页,共 64 页
上一页
下一页